HeartBeam Inc. (NASDAQ: BEAT) reported second-quarter 2026 financial and operational results, highlighting significant progress across its heart attack detection program, 12-lead ECG extended wear patch, and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026, and surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study. These milestones underscore the company's commitment to advancing the detection and monitoring of critical cardiac conditions.
HeartBeam also completed a working prototype of its 12-lead ECG extended wear patch, a key component of its platform technology. The company has signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients. This initial commercial launch marks a pivotal step in bringing its innovative technology to market.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, compared with a net loss of $5 million, or $0.15 per share, a year earlier. Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026. The company expects full-year 2026 net operating cash outflow to be below $14 million, extending its cash runway into 2027. This financial discipline provides the company with the resources to continue its research and development efforts and commercial expansion.
The company's progress is particularly notable given the recent FDA clearances. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025 (1). These clearances validate the company's innovative approach to cardiac monitoring.
The implications of HeartBeam's advancements are significant for the medical technology industry and for patients. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining the future of cardiac health management.
The completion of the ALIGN-ACS pilot study and the progress in the HEADSTART-ACS study are critical steps toward regulatory approval and commercial availability. If successful, these studies could lead to a more accessible and timely detection of heart attacks, potentially saving lives.
HeartBeam holds over 20 issued patents related to technology enablement, further solidifying its intellectual property position. The company's focus on innovation and its strategic commercial agreements position it well for future growth.
For more information on HeartBeam's technology and cleared indications, visit the company's website at https://www.heartbeam.com/indications. For the full press release, see https://ibn.fm/QjrtT.
